Reflections and resources on psychedelic science, holistic wellness, mental health, spirituality, and the work of personal growth.
The FDA’s September 2026 public hearing on the potential future use of psychedelic drugs asked questions about how these treatments should be delivered. Here, I reflect on what the hearing revealed about psychotherapy, provider training, accessibility, and the future of integrated psychedelic care.
The implications of Definium's phase III clinical trials on the role of psychotherapy in psychedelic treatment models.
